Company Overview and News

0
Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results

20h globenewswire
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal first-quarter 2019 operating and financial highlights. In advance of the call on August 9, 2018, Organovo will issue its fiscal first-quarter 2019 earnings press release, which will be available at http://www.
ONVO

0
Organovo Shareholders Could Have Even More Downside Ahead

2018-07-03 seekingalpha
Organovo Holdings (ONVO) is potentially 2-3 years away from a multi-billion-dollar revenue stream from their treatments for liver diseases.
DDD SSYS ONVO

52
ONVO / Organovo Holdings, Inc. DEF 14A

2018-06-15 sec.gov
onvo-def14a_20180726.htm UNITED STATES
ONVO

58
ONVO / Organovo Holdings, Inc. DEFA14A

2018-06-15 sec.gov
onvo-defa14a_20180726.htm
ONVO

48
Organovo Holdings: A Small Biotech At A Great Valuation

2018-06-08 seekingalpha
Organovo Holdings is a small biotech company that recently traded at all-time lows, despite the company reaching an important milestone.
ONVO

69
ONVO / Organovo Holdings, Inc. PRE 14A

2018-06-01 sec.gov
onvo-pre14a_20180601.htm UNITED STATES
ONVO

46
Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2018 Results - Earnings Call Transcript

2018-06-01 seekingalpha
Good day, everyone and welcome to the Organovo Holdings, Inc. Fourth Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded.
ONVO

61
5 Top Performing Stocks From May’s Best ETF

2018-05-31 investorplace
ARK Genomic Revolution Multi-Sector ETF ARKG topped the list of the best performing ETFs of May, with impressive returns of about 13.6%. The rally was mainly driven by tax reform, rising M&A and positive regulatory backdrop.
NSTG ONVO CRSP FMI

53
ONVO / Organovo Holdings, Inc. 10-K (Annual Report)

2018-05-31 sec.gov
onvo-10k_20180331.htm
ONVO

48
ONVO / Organovo Holdings, Inc. 8-K (Current Report)

2018-05-31 sec.gov
onvo-8k_20180531.htm UNITED STATES SECURITIES AND
ONVO

46
Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019

2018-05-31 globenewswire
- Lead Investigational New Drug (“IND”) program for Alpha-1-antitrypsin deficiency (“A1AT”) received FDA’s orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019
ONVO

79
5 Top Performing Stocks of the Best ETF of May

2018-05-31 zacks
ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) topped the list of the best performing ETFs of May, with impressive returns of about 13.6%. The rally was mainly driven by tax reform, rising M&A and positive regulatory backdrop. The new tax legislation has enticed large pharmaceutical companies to bring offshore cash back home at reduced tax rates of 8-15.5% instead of the prior 35%. The repatriated money has led to an increase in mergers and acquisitions activity, share buybacks and dividends.
ARKG NVTA NSTG ONVO CRSP FMI

46
ONVO / Organovo Holdings, Inc. / ARK Investment Management LLC - SC 13G/A (Passive Investment)

2018-05-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ONVO

51
ONVO / Organovo Holdings, Inc. / ARK Investment Management LLC - SC 13G/A (Passive Investment)

2018-05-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ONVO

46
ONVO / Organovo Holdings, Inc. null

2018-05-17 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;[email protected]_C"O_ 08 ##?#0<-"F5N9'-T
ONVO

ONVO : Organovo Holdings Stock Analysis and Research Report

2017-10-30 - Asif

Organovo Holdings, Inc. is an early commercial stage company focused on developing and commercializing functional three-dimensional (“3D”) human tissues. Using its proprietary technologies and expertise in bioprinting, Organovo Holdings is building functional 3D human tissues that mimic key aspects of native biology, and can be used in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. Organovo Holdings is utilizing its proprietary bioprinting platform to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Organovo Holdings is leveraging its unique tissue models to improve the current industry standard cell-based and animal model testing approaches, and the company believe its foundational approach provides it with the opportunity to fill many critical gaps in commercially available preclinical human tissue models as well as in tissue trans...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ONVO / Organovo Holdings, Inc. on message board site Silicon Investor.

Organovo (ONVO)
CUSIP: 68620A104